C520 Stock Chart & Stats
€22.60
-€0.20(-0.88%)
At close: 4:00 PM EDT
€22.60
-€0.20(-0.88%)
Day’s Range― - ―
52-Week Range€17.40 - €28.40
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€1.43B
Enterprise Value€2.68K
Total Cash (Recent Filing)€33.13M
Total Debt (Recent Filing)€1.41B
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Aug 06, 2026EPS Estimate
0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-20.02
Shares Outstanding57,562,603
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)1.02
Price to Sales (P/S)0.67
P/FCF Ratio75.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€36.14Price Target Upside59.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)3.2
Revenue Forecast (FY)€2.06B
Bulls Say, Bears Say
Bulls Say
High Gross MarginsA sustained ~60% gross margin provides durable earnings leverage as revenue grows. High product margins give Enovis flexibility to fund R&D, support integration of acquisitions, and absorb some cost inflation while aiming to convert improving top-line into durable operating profit over the medium term.
Recon Segment Leadership & InnovationRecon's consistent outperformance (U.S. Recon organic growth +8%, extremities +10%) plus new systems (Nebula, ARG) and Arvis adoption create sustainable competitive advantages. Momentum in ASCs and instrument set rollouts increases procedure share, recurring instrumentation revenue, and long-term market penetration.
Improving Cash Generation And Balance SheetPositive and growing free cash flow, together with materially lower leverage versus 2024–2025, enhances financial flexibility. A >25% FCF conversion target supports reinvestment in Recon, disciplined CapEx, debt reduction or shareholder returns and reduces refinancing risk over the coming 2–6 months.
Bears Say
Severe Operating And Net LossesThe swing to very large operating losses and deep negative net margins undermines return metrics and implies the cost base currently outstrips revenue. Until structural cost control or profitable scale is sustained, negative earnings will constrain reinvestment, credit metrics, and long-term investor confidence.
Tariff And Geographic ExposureOngoing tariffs and regional disruptions create persistent margin pressure and revenue volatility. $4M of recurring tariff costs and multi‑month Middle East exposure can erode adjusted margins and make forward forecasting harder, particularly for P&R categories with lower organic growth.
Non-GAAP Comparability Reduced By SEC-driven ChangeThe SEC-driven change to exclude inventory step-up adjustments reduces historical non‑GAAP comparability and complicates trend analysis of adjusted margins. This structural reporting shift raises transparency and modeling challenges and may affect stakeholder assessment of recurring profitability.
Enovis News
C520 FAQ
What was Enovis’s price range in the past 12 months?
Enovis lowest stock price was €17.40 and its highest was €28.40 in the past 12 months.
What is Enovis’s market cap?
Enovis’s market cap is €1.43B.
When is Enovis’s upcoming earnings report date?
Enovis’s upcoming earnings report date is Aug 06, 2026 which is in 7 days.
How were Enovis’s earnings last quarter?
Enovis released its earnings results on May 07, 2026. The company reported €0.781 earnings per share for the quarter, beating the consensus estimate of €0.713 by €0.068.
Is Enovis overvalued?
According to Wall Street analysts Enovis’s price is currently Undervalued.
Does Enovis pay dividends?
Enovis does not currently pay dividends.
What is Enovis’s EPS estimate?
Enovis’s EPS estimate is 0.74.
How many shares outstanding does Enovis have?
Enovis has 57,562,603 shares outstanding.
What happened to Enovis’s price movement after its last earnings report?
Enovis reported an EPS of €0.781 in its last earnings report, beating expectations of €0.713. Following the earnings report the stock price went up 2.941%.
Which hedge fund is a major shareholder of Enovis?
Currently, no hedge funds are holding shares in DE:C520
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enovis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€36.14 (59.90% Upside)
€36.14 (59.90% Upside)
Blogger Sentiment
Bullish
DE:C520 Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $92.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.57%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-21.39%
Trailing 12-Months
Company Description
Enovis
Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionals—including orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainers—who treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulators for pain alleviation, and physical rehabilitation equipment. Additionally, Enovis provides a comprehensive array of reconstructive joint implants for areas such as the hip, knee, shoulder, elbow, foot, ankle, and fingers. Enovis Corporation distributes its products through a network of independent channels, including healthcare providers, retail establishments, and pharmacies, in addition to direct sales under its prominent DJO brand. Previously known as Colfax Corporation, the company is headquartered in Wilmington, Delaware.
C520 Company Deck
C520 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call showed solid operational execution and clear commercial momentum—particularly in Recon and extremities—with meaningful innovation catalysts (Arvis, Nebula), margin expansion at the gross level, EPS growth, and improved free cash flow. However, offsetting risks include tariff costs (~$4M), international volatility including Middle East exposure (~$1–2M/month), a Q1 selling-days headwind (~240 bps), a conservative stance on guidance, and an SEC-driven change to adjusted EBITDA presentation that reduces non-GAAP comparability. On balance, positive fundamental performance and a constructive outlook outweigh the near-term headwinds and reporting adjustments.View all DE:C520 earnings summariesC520 Stock 12 Month Forecast
Average Price Target
€36.14
▲(59.90% Upside)